Investing.com - Morphosys AG reported on Monday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Morphosys AG announced earnings per share of €-2.13 on revenue of €29M. Analysts polled by Investing.com anticipated EPS of €-2.44 on revenue of €30.94M.
Morphosys AG shares are down 19% from the beginning of the year and are trading at €75.190 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 6.74% from the start of the year.
Morphosys AG follows other major Healthcare sector earnings this month
Morphosys AG's report follows an earnings missed by Merck on March 5, who reported EPS of €1.56 on revenue of €4.6B, compared to forecasts EPS of €1.57 on revenue of €4.51B.
Bayer had beat expectations on February 25 with fourth quarter EPS of €1.32 on revenue of €10B, compared to forecast for EPS of €1.26 on revenue of €10.13B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar